Sumitomo bets on Roivant to solve its patent expiry woes
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Myovant punished for success
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Upcoming events – pivotal readouts for Intra-Cellular and Myovant
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Bayer puts the brakes on vilaprisan trials following safety concerns
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.